Dagrocorat (developmental code names PF-00251802, PF-251802) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed.

[1][2][3][4] It is described as a partial agonist and "dissociable" agonist of the glucocorticoid receptor.

[5][6] The drug reached phase I clinical trials prior to the discontinuation of its development.

[1][3][4] The C2α dihydrogen phosphate ester of dagrocorat, fosdagrocorat, was also under investigation, but its development was terminated as well.

This hormonal preparation article is a stub.